Journal ArticleDOI
American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016
Pauline M. Camacho,Steven M. Petak,Neil Binkley,Dima L. Diab,Leslie S. Eldeiry,Azeez Farooki,Steven T. Harris,Daniel L. Hurley,Jennifer J. Kelly,E. Michael Lewiecki,Rachel Pessah-Pollack,Michael R. McClung,Sunil J. Wimalawansa,Nelson B. Watts +13 more
TLDR
A large number of the patients in this study had atypical femur fracture and the results confirmed the need for further investigation into the mechanisms leading to and effects of these fractures.About:
This article is published in Endocrine Practice.The article was published on 2016-09-19. It has received 768 citations till now. The article focuses on the topics: Guideline & Evidence-based medicine.read more
Citations
More filters
Journal ArticleDOI
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Donna K. Arnett,Roger S. Blumenthal,Michelle A. Albert,Andrew B. Buroker,Zachary D. Goldberger,Ellen J. Hahn,Cheryl Dennison Himmelfarb,Amit Khera,Donald M. Lloyd-Jones,J. William McEvoy,Erin D. Michos,Michael D. Miedema,Daniel Muñoz,Sidney C. Smith,Salim S. Virani,Kim A. Williams,Joseph Yeboah,Boback Ziaeian +17 more
TL;DR: Patrick T. O’Gara, MD, MACC, FAHA, Chair Joshua A. Beckman,MD, MS, FAha, Chair-Elect Glenn N. Levine, MD., Immediate Past Chair Sana M. Al-Khatib, MD.
Journal ArticleDOI
Therapeutic peptides: Historical perspectives, current development trends, and future directions.
Jolene L. Lau,Michael K. Dunn +1 more
TL;DR: An overview of the peptide therapeutic landscape is provided, including historical perspectives, molecular characteristics, regulatory benchmarks, and a therapeutic area breakdown, which includes over 150 peptides in active development today.
Journal ArticleDOI
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Donna K. Arnett,Roger S. Blumenthal,Michelle A. Albert,Erin D. Michos,Andrew B. Buroker,Michael D. Miedema,Zachary D. Goldberger,Daniel Muñoz,Ellen J. Hahn,Sidney C. Smith,Cheryl Dennison Himmelfarb,Salim S. Virani,Amit Khera,Kim A. Williams,Donald M. Lloyd-Jones,Joseph Yeboah,J. William McEvoy,Boback Ziaeian,Aha Task Force Members,Patrick T. O'Gara,Joshua A. Beckman,Glenn N. Levine,Sana M. Al-Khatib,Mark A. Hlatky,Kim K. Birtcher,John S. Ikonomidis,Joaquin E. Cigarroa,Jose A. Joglar,Anita Deswal,Laura Mauri,Lee A. Fleisher,Mariann R. Piano,Federico Gentile,Barbara Riegel,Duminda N. Wijeysundera +34 more
Journal ArticleDOI
Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force,Susan J. Curry,Alex H. Krist,Douglas K Owens,Douglas K Owens,Michael J. Barry,Aaron B. Caughey,Karina W. Davidson,Chyke A. Doubeni,John W. Epling,Alex R. Kemper,Martha Y. Kubik,C. Seth Landefeld,Carol M. Mangione,Maureen G. Phipps,Michael Pignone,Michael Silverstein,Melissa A. Simon,Chien-Wen Tseng,John B. Wong +19 more
TL;DR: The USPSTF found that the evidence is inadequate to assess the effectiveness of drug therapies in reducing subsequent fracture rates in men without previous fractures, and recommends screening for osteoporosis with bone measurement testing to prevent osteooporotic fractures in women 65 years and older.
Journal Article
Osteoporosis: A Review of Treatment Options.
Kristie N. Tu,Janette D. Lie,Chew King Victoria Wan,Madison Cameron,Alaina G. Austel,Jenny K. Nguyen,Kevin Van,Diana Hyun +7 more
TL;DR: In this article, a review of cost-effectiveness literature on the efficacy of oral bisphosphonates has shown alendronate and risedronate to be most cost-effective in women with low BMD without previous fractures.
References
More filters
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI
Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline
Michael F. Holick,Neil Binkley,Heike A. Bischoff-Ferrari,Catherine M. Gordon,David A. Hanley,Robert P. Heaney,M. Hassan Murad,Connie M. Weaver +7 more
TL;DR: Considering that vitamin D deficiency is very common in all age groups and that few foods contain vitamin D, the Task Force recommended supplementation at suggested daily intake and tolerable upper limit levels, depending on age and clinical circumstances.
Journal ArticleDOI
Risk factors for falls among elderly persons living in the community.
TL;DR: It is concluded that falls among older persons living in the community are common and that a simple clinical assessment can identify the elderly persons who are at the greatest risk of falling.
Journal ArticleDOI
Osteoporosis prevention, diagnosis, and therapy
Anne Klibanski,Lucile L. Adams-Campbell,Tamsen Bassford,Steven N. Blair,Scott D. Boden,Kay Dickersin,David R. Gifford,Lou Glasse,Steven R. Goldring,Keith A. Hruska,Susan R. Johnson,Laurie K. McCauley,William E. Russell +12 more
TL;DR: Though prevalent in white postmenopausal women, osteoporosis occurs in all populations and at all ages and has significant physical, psychosocial, and financial consequences.
Journal ArticleDOI
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Robert M. Neer,Claude D. Arnaud,Jose R. Zanchetta,Richard L. Prince,Gregory A Gaich,Jean-Yves Reginster,Anthony B. Hodsman,Erik Fink Eriksen,Sophia Ish-Shalom,Harry K. Genant,Ouhong Wang,Bruce H. Mitlak +11 more
TL;DR: Treatment of postmenopausal osteoporosis with parathyroid hormone decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated.